Item 8.01. Other Events.

Prior to and in connection with Hyperion Therapeutics, Inc.'s (the "Company") initial public offering of its common stock in July 2012, all of the Company's executive officers and directors and substantially all of its stockholders entered into lock-up agreements with the underwriters of the initial public offering pursuant to which they agreed not to dispose of any of the Company's securities, whether now owned or hereinafter acquired, for a period of 180 days after the public offering date, July 25, 2012 (the "Initial Lock-Up Period"), subject to extension under certain circumstances (the "Lock-Up Agreements"). The Lock-Up Agreements provide that if, during the last 17 days of the Initial Lock-Up Period, the Company announces material news, the Initial Lock-Up Period will be automatically extended until the expiration of the 18-day period beginning on the date of release of such news. On January 16, 2013, the Company announced that it received a communication from the U.S. Food and Drug Administration advising the Company that it should not to expect to receive a final action by the Prescription Drug User Fee Act (PDUFA) action date of January 23, 2013. As a result of the announcement on January 16, 2013, the Initial Lock-Up Period under the Lock-Up Agreements has automatically been extended through the close of business on February 3, 2013.

---